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ABSTRACT
We have carried out a structural and functional analysis
on the human NF-L (H-NF-L) gene. It contains a
methylation-free island, spanning the 5' flanking
sequences and the first exon and a number of neuronal-
specific DNase I hypersensitive sites have been
identified in the upstream region as well as within the
body of the gene. Analysis in cell lines and transgenic
mice using a combination of these sites has revealed
the presence of a conserved element(s) between
- 300bp and - 190bp which is required for neuronal-
specific expression.
INTRODUCTION
Neurofilaments (NFs) are neuron-specific intermediate filamnents
that are composed of three proteins with apparent molecular
weights of 68000 (NF-L), 145000 (NF-M), and 200000 (NF-H)
as determined by SDS-gel electrophoresis (for review, see 1).
Expression of NFs occurs as early as 9-10 days of gestation
in the mouse central and peripheral nervous system and coincides
with the appearance of postmitotic neurons (2). The genes are
differentially regulated during development; for example, NF-L
and NF-M genes are expressed early in the embryo, with a
progressive increase during development, while the NF-H mRNA
accumulates to significant levels only post-natally (3). Analysis
of their expression in pheochromocytoma PC 12 cells which
mimicks neuronal development has shown that the NF-L and NF-
M genes are at least in part controlled at the level of transcription,
whereas the induction of NF-H by nerve growth factor is
controlled post-transcriptionally (4,5).
Sequence analysis of a genomic clone of the human NF-L gene
has shown that a 6.5kb EcoRI fragment contains all of the coding
sequence and one of the polyadenylation sites (6). This fragment
also contains 2.3kb of 5' flanking sequence. The human NF-L
promoter has a typical TATA box 30bp upstream of the cap site
and a potential SpI binding site at - llObp, relative to the cap
site. The promoter and the first exon are very GC-rich especially
in the region from -300bp and +200bp from the cap site (64%).
This is a typical feature of methylation-free islands, which are
present at the 5' end of a large number of genes (7,8).
We report here the characterization of the promoter of the
human NF-L gene. We show that the gene has a number of
neuronal-specific DNase I hypersensitive sites in the 5' flanking
sequence and within the body of the gene. To assess the role
of some of these hypersensitive sites, the expression of a number
of deletion constructs have been analysed both in cells and
transgenic mice. These experiments demonstrate the presence of
a brain-specific element(s) between -300bp and -l90bp relative
to the cap site which is conserved between the human and mouse
genes.
MATERIALS AND METHODS
Constructs
The human NF-L constructs are cloned into pUC19 unless
otherwise stated. The promoter deletions are as follows: The
-2300bp construct contains 2300bp 5' upstream sequence and
is identical to the sequenced 6.5kb EcoRI fragment (6). The
-300bp construct is deleted to a BamHI site which is -300bp
from the cap site and extends downstream as far as the RI site
in the last exon (IV). The -300 Sal construct contains the same
-300bp promoter deletion, but extends to a SalI site which is
3. lkb downstream ofthe RI site in exon IV. The -300 Sal 5'ESV
and -300 Sal 3'ESV constructs contain a 220bp NcoI-PvuII
fragment from the SV40 enhancer which was modified by
addition of linkers to either a BamHI fragment or a SailI fragment
and placed at the 5' and 3' end of the -300 Sal construct,
respectively. The -l90bp, -90bp and -70bp deletion mutants
contain l90bp, 90bp and 70bp promoter fragments, respectively
linked to the rest of the gene and were generated using restriction
enzyme sites ApaI, BssHII and NaeI, respectively. These were
also modified by linker addition so as to contain a BamHI
recognition sequence. The -55bp deletion mutant contains 55bp
of promoter fragment and was generated by Bal3l digestion of
the -300bp construct. The construct lacking the first intron
hypersensitive sites was prepared by deleting a lkb BailI-StuI
fragment from the first intron of the -300bp construct. The
human Thy-I gene used for C1300 transfections was a kind gift
of Dr.E.Spanopoulou and the human ,B-globin construct used as
cotranfection control in the HeLa transfections was as described
(9).
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DNase I hypersensitive site mapping
DNase I sensitivity assays were carried out as described by Enver
et al. (10) with the modification described by Grosveld et al. (11).
DNA was prepared from DNase I-treated nuclei using the
procedure of Luster and Ravetch (12).The probes used for
Southern analysis of this DNA are described in the corresponding
figure legends.
Cell culture and transfections and RNA analysis
HeLa and C1300 cells (13) were obtained from the American
Type Culture Collection and were grown in a-MEM
supplemented with 10% foetal calf serum. Gene transfer was
performed by calcium phosphate co-precipitation (14,15). 30tg
of supercoiled DNA were used per 90mm plate (106 cells). The
calcium phosphate-DNA was left on the cells for 12- 16 hours
then the medium was changed and the cells harvested 48 hours
after transfection for RNA preparation.
RNA extraction of the transfected cells was performed in 3M
lithium chloride, 6M urea including a 5 minute sonication step
(41). DNA SI probes were end labelled at one end with T4
polynucleotide kinase (Boehringer Mannheim) and y32p-ATP
(3000 cu/mmole, New England Nuclear) or fill-in with reverse
transcriptase (Super RT, Anglia-Biotec) and the appropriate
a32p-labelled deoxynucleotide triphosphate (6000 ci/mmole,
New England Nuclear). Restriction fragments used as probes are
described in the corresponding figure legends. Hybridisation and
S1 protection reactions were carried out as described previously
(16,17, also see below).
Transgenic mice: DNA and RNA analysis
DNA fragments containing human NF-L gene were isolated free
from vector sequences by preparative agarose gel electrophoresis
and injected into pronuclei of fertilized oocytes from
(CBAXC57BL/10) Fl mice at a concentration of 1-2 ytg/ml
of TE buffer (1OmM Tris (pH7.5), 0.2mM EDTA). Eggs
surviving microinjection were transfered into oviducts of recipient
pseudopregnant females (18).
In all the analyses the presence of human NF-L DNA in the
offspring of the founder mice was determined by Southern blot
analysis (19) of DNA extracted from the tails or in the case of
younger mice either placenta or liver. Hybridisation with a 2.2kb
SstI probe, spanning exon one through three of the NF-L gene,
was used for detection of the human signal. The copy number
of the transgene was estimated in the offspring by comparison
to the 2 copy signal obtained from human placental DNA.
For expression analyses, transgenic lines were established and
total RNA was prepared from various tissues, including brain
kidney, liver, lung, spleen, thymus and testis or ovaries (41) and
subjected to S1 nuclease protection assay. Mixed probes (a 350bp
RsaI 5' human NF-L and a 270bp XmaI 5' mouse NF-H) were
used to detect correctly initiated transcripts from the transgene
as well as the endogenous mouse NF-H RNA. Hybridization was
performed at 600C in 80% formamide and the samples were
digested at 370C for 2 hours using lOOu of S1 nuclease. SKNSH
RNA was used as the positive control to detect the human NF-L
protected fragment of 121 nucleotides (nt). To control for possible
differences in the brain RNA levels, a 5' end-labelled mouse NF-
H (m-NF-H) probe was used which gives a protected fragment
of 160nt.
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Fgure 1. DNaseI hypersensitive site mapping of the human NF-L gene.Left panel:
Nuclei from K562 cells were isolated and treated with 20,ug/ml of DNaseI for
increasing lengths of time (t) from 0 to 20 minutes at 37 (indicated by a gradient
above each panel). DNA was digested with EcoRI, run on a 1% agarose gel,
blotted and probed with a 4.5kb BamHI-EcoRI (BHI-RI) probe A to detect the
presence of hypersensitive sites (HS) in the gene. 0 indicates no DNase treatment.
The size of marker fragments is indicated on the left in kdlobases. Left S-KN-
SH: An EcoRI (RI) blot of a series of DNaseI-digested nuclei from S-KN-SH
cells was probed with probe A of the human NF-L gene. Treatment was as above.
Hypersensitive sites are indicated on the right. Middle S-KN-SH: Reprobe of
the SKNSH panel with a 1.4kb RI-BHI probe B to detect 5' end HS sites. The
HS5 label indicated on the right is leftover signal from the previous panel. Right
S-KN-SH: SKNSH DNA was restricted with SstI run on a 1.5% agarose gel.
A 450bp SstI-XhoI probe C was used to detect the first intron HS sites 5A and
SB. The size markers are shown on the right hand side. Bottom panel: the map
of the human NF-L gene and the position of the HS sites 1-6. The fragments
used as probes (A-C) are drawn with respect to their position in the NF-L gene.
RESULTS
Chromatin structure of the human NF-L gene
The presence of a methylation-free island in the human NF-L
gene expected on the basis of high GC content was confirmed
by Southern blot analysis. The DNA was digested with the
methylation-sensitive enzyme Hpa-ll to show that the presence
of unmethylated CpG dinucleotides from - 1.7kb to +1.5kb
relative to the cap site in all tissues examined including germ-
line (data not shown).
We next localised all of the DNase I-hypersensitive sites witiin
a 6.5kb EcoR I fragment containing the human NF-L gene and
2.3kb of 5' flanking region. Since there are large populations
of non-neuronal cells in brain tissue, we used a neuronal cell
line to determine the position of these sites. Nuclei were prepared
from an NF-L expressing (SKNSH) and non-expressing (HeLa
and K562) human cell lines and subjected to limited DNaseI
digestion. DNA was isolated, digested with various restriction
enzymes, subjected to Southern blotting and hybridised to several
probes spanning the entire NF-L gene. When EcoRI-digested
DNA was hybridised with the 3' 4.5kb EcoRI-BamHI probe A
(figure 1, left panels), several hypersensitive sites (HS3 -6) were
observed in DNA isolated from the SKNSH cells, but none with
the non-neuronal HeLa (data not shown) or K562 DNA. As a
control the K562 blot was also probed with a ,B-globin probe to
show the presence of the locus activating region hypersensitive
sites (data not shown, 42). When hybridised with a probe from
the 5' end of the EcoRI fragment (probe B), the positions of the
three promter hypersensitive sites were mapped to -1.1kb (HS1),
-900bp (HS2) and -250bp (HS3) (figure 1, middle).
q
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Hybridisation of SstI digested DNA with the 450bp SstI-XhoI
probe C (figure 1, right) further resolved the strongest
hypersensitive site (HS5) into two subsites, HS5A and HS5B,
which are lOObp apart and are situated in the first intron around
position +3600bp (relative to the cap site). The two weaker sites
(HS4 and HS6) were mapped to be at +3400bp, in the first exon
and at +5000bp, in the second intron. The positions of the six
nerve-specific hypersensitive sites are summarised in figure 1.
Transient transfections in HeLa cells
Based on the location of DNase I hypersensitivity sites and
sequence homology to the promoter of the mouse NF-L gene
(20) a number of deletions of the human NF-L gene were cloned
in pUC and tested by transfection in HeLa cells (figure 2). As
a control the gene with the -300bp deletion was also cloned
upstream and downstream of SV40 enhancer to drive expression
in HeLa cells (-300Sal in pBSV, -300 Sal 5'ESV and 3'ESV,
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respectively). All NF-L plasmids were cotransfected with a
human 3-globin gene (9) to control for transfection effeciency.
The results show that the NF-L gene is expressed at low levels
in tis transient assay system unless driven by the SV40 enhancer.
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Figure 3. Expression analysis of human NF-L promoter deletions in transiently
transfected C1300 cells. Human NF-L deletion constructs (see figure 2) were
co-transfected with a human Thy-i construct into mouse C1300 neuroblastoma
cells by the calcium phosphate precipitation method. The cells were harvested
after 48 hours and total RNA was analysed by an Si nuclease protection assay
as follows: 50,ag of RNA was hybridised to a mixture of the following probes:
i) a 980bp BstEln-ApaI endlabelled 3' human Thy-i (h-Thyl) probe spanning
exon m and IV and ii) a 350bp RsaI end-labelled 5' human NF-L probe.
Hybridisation was carried out at 54°C in 80% formamide after which the products
were digested at 25°C for 2 hours using iOOu of SI nuclease and analysed by
fractionation on a denaturing polyacrylamide gel. Protected fragments of 121nt
for the human NF-L gene and 320nt for the human Thyl gene are indicated by
arrows. The uppermost arrow indicates the position of rehybridised 350bp human
NF-L input probe. Transfer RNA (tRNA), C1300 and HeLa RNA were used
for negative controls. A construct lacking a promoter (-20bp) was used as negative
control. GRK is a kidney tumour derived cell line expressing human Thy-I RNA
(40) and RNA prepared from this line was used as a positive control for the human
Thy 1 mRNA protected fragment. The marker (M) is end-labelled Hinfl digested
pBR322.
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Figure 2. Expression analysis of Human NF-L promoter deletions in transiently
transfected HeLa cells. Upper panel: The various human NF-L promoter deletions
were co-transfected with a human (3-globin gene in a pBSV-based vector (9) by
the calcium phosphate precipitation method into HeLa cells. The cells were
harvested after 48 hours, total RNA prepared and expression analysed by SI
nuclease protection as follows: Between 50- 10O0sg of RNA was hybridised to
a mixture of two end-labelled probes,a 2.5kb EcoRI-XmaI 5' human NF-L probe,
and a 750bp EcoRI-MspI third exon ,B-globin probe at 54°C for 16 hours, followed
by digestion with 100u of SI nuclease at 25°C for 2 hours. The samples were
then fractionated on a 6% denaturing polyacrylamide gel. SKNSH RNA was
included as the positive control for the human NF-L protected fragment of 154
nucleotides (nt), while RNA from HeLa cells transfected with the ,B-globin gene
alone was used as the positive control for the (3-globin 212 nt signal, both indicated
by arrows. As negative control, RNA from untransfected HeLa cells (mock) was
used. Lower panel: Maps of the wild type human NF-L gene from the EcoRI
(RI) site which is 2300bp upstream of the startsite, to a SailI site which is 3. lkb
downstream of the RI site in exon 4 as well as the promoter deletions used in
this study (see also Materials and Methods).
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Figure 4. Analysis of a -2300bp human NF-L promoter deletion in adult
transgenic mouse lines. Various lines of transgenic mice bearing the -2300 bp
human NF-l promoter deletion construct were established as described in Materials
and Methods. Total RNA was prepared from various tissues of two month old
offspring from transgenic mice lines 6, 13, 1 and 14, as well as an aged-matched
non-transgenic (N-Tg) mouse. 40 yg of RNA was hybridised with a mixture of
two probes:i) a 350bp RsaI end-labelled 5' human NF-L (HNF-L) to detect the
transgene and ii) a 270bp XmaI end-labelled 5' mouse NF-H (MNF-H) probe
to correct for possible differences in the mRNA levels. The specific activity of
the MNF-H was twice that of the HNF-L probe. Hybridisation was performed
at 60°C in 80% formamide and the samples were digested at 37°C for 2 hours
after which the protected fragments were fractionated by denaturing polyacrylamide
gel electrophoresis. Protected bands of 160 nucleotides for the endogenous mNF-H
and 121 nucleotides for the transgene. SKNSH RNA was used as the positive
control for the transgene signal. Abbreviations: brain (B), kidney (K), liver (L),
spleen (S), ovaries (0), testes (Te), and thymus (T).
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Figure 5. Expression analysis of -300bp and -55bp human NF-L promoter deletions in transgenic mice. Left panel: Transgenic lines were established for both
the -300 and -55 human NF-L promoter deletions. Total RNA was prepared from several tissues of five transgenic mouse lines 1, 7, 8, 9 and 16 carrying the
-55bp promoter deletion as well as four transgenic mouse lines 6, 12, 13, and 20 carrying the -300bp deletion. RNA was hybridised to mixed probes for SI
nuclease protection assay as described for figure 4. Positions of protected bands of 160nt for the mouse NF-H (mNF-H) and 121nt for the transgene (HNF-L) as
well as the reannealed input probes are indicated by arrows. Non-transgenic brain RNA (nTgB) was used as a positive control for the endogenous mNF-H signal
and negative control for transgene expression while SKNSH RNA as positive control for the human NF-L protected fragment and negative control for the mNF-H
protected fragment. TgB is brain RNA from a transgenic line (-2.3 line 6) containing the -2300bp construct (figure 3) and serves as a positive control for endogenous
and transgene signals. Abbreviations: brain (B), kidney (K), liver (L), spleen (S), testes (Te), thymus (T). Extreme right: SI nuclease protection was performed
on RNA isolated from various tissues of a two month old transgenic mouse (-300 deletion line 6) and its newborn offspring (a, b and c) as described in figure
4. Control tracks are as described for left panel except that the transgenic brain (TgB) RNA positive control is derived from transgenic line 13 carrying the -300bp
construct (see left panel). In addition the transfer RNA (tRNA) track serves as a control for nonspecific probe digestion products. Newborn mice b and c carry
the transgene, but mouse a does not contain the transgene (data not shown) and therefore serves as an additional negative control for transgene expression. nTg
RNA from various tissues of an age-matched non-transgenic newborn mouse was also analysed. Abbreviations: brain (B), liver (L). The figures on the right side
of the figure are size markers (M) of pBR322 digested with Hinfi and end-labelled.
Nevertheless, the activity of the promoter in the absence of a
SV40 enhancer is sufficiently high to observe that activity is only
increased two to three fold when the promoter is deleted from
-300 to - l90bp. Further deletions which leave less than 90bp
of the promoter result in a very low level of expression,
suggesting the presence of a basic promoter element between -90
and -70 which is required for expression in this heterologous
cell type. Although we have not rigorously confirmed this,
preliminary footprinting experiments (data not shown) indicate
that this region may contain a protein binding site present in HeLa
cells, but not SKNSH cells. More importantly, we conclude from
this experiment that deletions of the promoter regions (-2.3kb
to -300bp) which contain neuronal-specific hypersensitive sites
either have no effect or appear to increase rather than decrease
expression in HeLa cells.
Transient expression in C1300 cells
To be able to analyse the promoter deletion constructs in neuronal
cells, we tested a number of cell lines for their transfection
efficiency. Six NF positive cell lines were used: PC12 (21),
SKNSH (22), B104 (23), C1300 (13) SMS-KCNR and SMS-
KAN (24) of which C1300 gave the highest transfection efficiency
and this cell line was therefore used for the analysis of the NF-L
mutant constructs. The human Thy-i gene which is expressed
in neuronal cells in vivo (25) was used as a control. Fig. 3 shows
that the deletion of the upstream promoter (-2300bp to -300bp)
enhances the expression of NF-L when compared to the Thy-i
control. A similar result has been reported by Shneidman et
al. (26). A further deletion to -l90bp leads to a strong decrease
in NF-L expression, indicating the presence of a neuron-specific
positive element. Further deletion to -90 and/ or -55 leads to
a further small decrease in activity. Interestingly even the -55bp
promoter construct retains a low level of transcriptional activity.
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Figure 6. Analysis of -190bp human NF-L promoter deletion in transgenic mice.
Three transgenic lines of mice bearing the -190 human NF-l promoter deletion
(lines 1, 6 and 18) were established and the expression of the transgene in these
lines was examined as described in figure 5. To compare expression levels, brain
RNA from transgenic line 6 (designated Tg-300 B) carrying the -300bp deletion
(see figure 5) was included in the analysis. Other controls include RNA isolated
from tissues of an age-matched non-transgenic mouse brain RNA designated nTgB.
Input indicates reannealed probe. Abbreviations: brain (B), kidney (K), liver (L),
spleen (S), thymus (Th), testes (Te), lung (L).
Expression analysis in transgenic mice
Because the effects observed in the C1300 cells were small we
decided to analyse the effect of the promoter deletions which had
the most pronounced effects in cell culture in transgenic mice.
The first construct that we microinjected contained 2.3kb of 5'
flanking sequence linked to the rest of the HNF-L gene. It
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Figure 8. Comparison ofhuman and mouse NF-L promoter regions. The sequence
of the human NF-I promoter in the region of -300 to -180 was compared to
the homologous region in the mouse gene. Dashes indicate identity of bases at
that position.
Figure 7. Analysis of -300bp human NF-L promoter deletion lacking the first
intron hypersensitive sites (HS5A and HS5B) in adult and embryonic stage
trangenic mice. A transgenic mouse line bearing a construct consisting of the
-300 NF-L promoter deletion as well as an internal Ball-Stul first intron deletion
was established. A total of 8 nine day (E9) embryo offspring from a mating between
a transgenic heterozygote and wild type mouse were dissected and RNA was
prepared from the head regions. Transgenic embryos (1 and 3) were identified
by Southern blot analysis of placental DNA (not shown) and the transgene
expression in transgenic (1,3) as well as non-transgenic (2, 4-8) E9 brain was
analysed by an Sl nuclease protection assay. Brain RNA from a two-month old
transgenic adult carrying the same construct (adult Tg) was also analysed in order
to compare the ratio of the NF-L transgene expression to that of the endogenous
NF-H. As a positive control for endogenous mNF-H expression as well as a
negative control for transgene expression RNA from the -55 deletion line 16
(see figure 5) designated -55bp Tg was analysed in parallel . The transfer RNA
(tRNA) track served as a control for nonspecific probe digestion products.
therefore contained the promoter hypersensitive sites (HS1, HS2,
and HS3) as well as the downstream hypersensitive sites. A total
of eight transgenic lines with varying transgene copy numbers
were generated (data not shown). We examined the expression
pattern of the transgene in four adult lines that contained the
highest copy numbers (see figure 4). SKNSH RNA was used
as the positive control to detect the human NF-L protected
fragment. The highest level of transgene expression occurs in
the brain, indicating that the regulatory sequences that direct
tissue-specific expression are present on this fragment (Figure 4).
In only one transgenic line (-2.3 line 13), there is ectopic
expression of the transgene in the thymus indicating that the gene
is sensitive to position effects (figure 4). A similar result has been
reported for mice bearing a transgene of 2.3kb of the 5' flanking
sequences linked to a CAT gene (27). To check for a
developmental role for these hypersensitive sites, the presence
of the transgene was tested in newborn mice and where it was
shown to be expressed (data not shown).
We next generated transgenic mice for a deletion containing
only 55bp of the promoter linked to the rest of the gene. This
construct therefore lacked the first three hypersensitive sites (HS1,
HS2 and HS3) but contained all the downstream HS sites. A
total of five transgenic lines were analysed (figure 5). It is clear
that -55bp H-NF-L construct is not expressed in the brain or
any other tissues examined even when it is present in multiple
copies (mouse # 1 carries 5 copies, data not shown). We then
tested four transgenic mice containing the -300bp promoter
which contains HS3, but not HSI and HS2 (figure 5). This
construct is expressed in a tissue-specific manner in all mice
examined, with the exception of mouse 13 which shows ectopic
expression in the kidney and thymus. This result demonstrates
that HS1 and HS2 are not essential for neural specific expression
of the HNF-L gene. We also tested the methylation pattern of
expressing (-300bp promoter deletion) and non-expressing
(-55bp promoter deletion) transgenes and found that both
transgenes were unmethylated to the same extent (data not
shown). This indicates that the transcriptional activity of the
transgenic mice is not reflected in the methylation state of the
transgenes. It also suggests that a much smaller region (about
half of the normal size) of the methylation-free island of the
human NF-L gene can still remain an island.
We also examined the expression of -300bp deletion construct
in younger mice using the NF-H gene as a control. The latter
gene is only expressed post-natally (3) and serves as a late
developmental marker. Newborn mice from transgenic line 6
were examined for HNF-L expression by S1 nuclease protection
assay and were shown to express the transgene in brain (figure
5). The lower intensity signal of the control mouse NF-H gene
relative to that of the NF-L transgene when compared to the two
month old mice is consistant with the known early expression
of NF-L during development. This result therefore argues against
a developmental role for hypersensitive sites HS1 and HS2.
To further determine the location of the neuronal tissue specific
element in the -300 promoter HNF-L promoter, we examined
(on the basis of the C 1300 cell transfection experiments) the
expression of a 5' deletion containing l9Obp ofupstream sequence
linked to the rest of the gene. We obtained three transgenic mice.
Only two of these mice expressed the transgene in the brain, but
at very reduced levels relative to those observed for the -300bp
mice (figure 6). Ectopic HNF-L expression was also detected
in both mice. We therefore conclude that an element important
for neuronal-specific expression has been lost by this deletion
and as a consequence that the transgene is more sensitive to
position-effects. However, the gene is still expressed at a low
level further emphasizing that the region between -190bp and
-55bp is important for basal expression.
It is clear from the results with the - 300bp promoter this
residual promoter fragment is sufficient to allow the HNF-L gene
to be expressed in a developmentally specific manner (figure 5).
However, we had previously shown that a 2.3kb HNF-L
promoter fragment linked to the Thy-i gene was not expressed
early in development, but rather mimicked the expression pattern
of the Thy-i gene (28). This suggested that either the NF-L gene
carries a developmental specific element in the gene or that a
known brain-specific element (in the first intron) of the Thy-i
imNF'H -
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gene has a dominant effect. The obvious candidate for such an
intragenic NF-L element would be the strong hypersensitive sites
HS5A and B. We therefore analysed the expression pattern of
a human NF-L gene construct containing 300bp upstream
promoter sequence linked to the rest of the gene but lacking the
first intron strong hypersensitive sites (HS5A and HS5B) (see
figure 2). Two transgenic mice were obtained of which only the
one carrying two copies of the gene could be established as a
line. This line was bred and total brain RNA was analysed from
a two month old transgenic mouse and 9 day embryos by SI
nuclease protection (figure 7). The developmental role for the
first intron was assayed by the ratio of HNF-L transgene RNA
to endogenous NF-H RNA. The two 9 day embryos which
carried the transgene both expressed the HNF-L transgene, but
not the NF-H endogenous gene whereas the two month old animal
expresses both genes (figure 7). We therefore conclude that
hypersensitive sites HS5A and HS5B are not required for the
correct developmental expression of the gene.
DISCUSSION
It has been shown for the murine NF-L gene, that 1.5kb of the
sequence upstream of the transcriptional start site is sufficient
to yield brain-specific expression of the homologous gene (29)
as well as heterologous genes (30) in transgenic mice. Further
promoter deletions have not been analysed for the murine NF-L
gene to permit a functional comparison to be made of the minimal
regulatory sequences that are needed for neuronal-specific
expression in human and mouse genes. Using large fragments
of flanking sequences, brain-specific expression has been
observed for a number of neuronal-specific genes in transgenic
mice (31,32,33,34,28), including the HF-H gene (35). However
in only one case has a functional element been defined to a very
small region. Analysis of neural-specific SCG1O promoter
sequences fused to a marker gene in transgenic mice (36) as well
as cell lines (37) has identified a silencer element in the 5' flanking
sequences. It has been proposed that neuronal specificity of the
SCG1O gene is achieved through selective repression in non-
neuronal tissues (36), making this an alternative mechanism for
gene activation in the nervous system.
We have studied the possible in vivo role of the hypersensitive
sites of the human NF-L gene by analysing the expression pattern
of a series of deletion constructs in transgenic mice and cultured
cells. Murine NF-L, NF-M and NF-H genes as well as the
chicken NF-M gene have recently been shown to be expressed
after transfection in non-neuronal cells (38,26,39). Using transient
transfections, negative regulatory regions were found between
-325 and -925 in the mouse NF-L gene as well as upstream
regions of the murine NF-M and NF-H genes that suppressed
transcription in both neuronal and non-neuronal cells (26). Since
these elements behave similarly in all cell types, their importance
in regulating NF expression remains unclear. We have also
observed an increase in expression upon deleting from -2300bp
to
-300bp in our transient assays in C1300 cells. In agreement
with the above mentioned data this effect is also observed in HeLa
cells. Although the expression level in the transgenic mice cannot
be strictly quantitated as a function of copy number, the average
expression per copy of the transgene is higher with the -300bp
promoter than with the -2300bp promoter. This result agrees
with that obtained in the transfections and we conclude that the
upstream region plays a negative regulatory role. It is not clear
however whether it has a neuronal-specific regulatory role,
because the data obtained in non neuronal cells were obtained
by transient transfections in cells that do not show any
hypersensitive sites in this region of the promoter of the
endogenous NF-L gene.
When the human NF-L promoter is deleted from -300bp to
- l90bp there is a clear negative effect on neuronal expression
of the gene both in transgenic mice and the cell cultures. Sequence
comparison reveals a high degree of homology between the mouse
and the human NF-L gene in the region between -300bp and
- 190bp (over 65%, figure 8). We have carried out preliminary
experiments on the biochemical characterization of the promoter
region and footprint data show that potential neuron cell specific
factor binding sites are centered around -230bp and -285bp
(data not shown).
A further deletion which leaves only a 55bp promoter including
a TATA box was still expressed, albeit at low levels in C1300
cells. However, the -55bp promoter is not expressed in
transgenic mice indicating that there are no downstream elements
capable of driving minimal expression. It is clear that HS5A and
HS5B are not required for the tissue-specific or temporal
regulation of the gene contrary to what has been suggested
previously (28) because the -300bp promoter when linked to
a gene which lacks HS5A and HS5B is still expressed correctly.
It is therefore not clear what role if any is played by the
downstream sequences which contain HS4, 5 and 6. Of course
the possibility remains that the sites HS5A and SB do fulfill an
as yet unclear function and that the other hypersensitive sites still
present in this construct may functionally substitute for the deleted
sites, reflecting a level of redundancy in the NF-L regulatory
sequences.
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